Cyxone plans to initiate a phase 2 clinical trial with Rabeximod in Covid-19 patients
Cyxone (publ), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, announces today that it plans to initiate a phase 2 clinical trial with Rabeximod in Covid-19 patients. The treatment is intended to reduce the risk of developing severe respiratory symptoms caused by virus-related overactivation of the immune system.Most people with Covid-19 experience only mild symptoms, but in severely affected patients the immune system overreacts, triggering a disproportional release of cytokines and chemokines that leads to hyperinflammation and severe